Also listed on Titan Pharmaceuticals, Inc., an earlier holder on the record. The recorded assignments below show how it moved.
Term ends no later than Mar 16, 2031 · Medium confidence
20-year base term ends Mar 16, 2031
In force on USPTO's status record and by its fee record. A terminal disclaimer on file may shorten this term, possibly to a date already past; its reference document is unresolved, so the date above is an upper bound and no earlier date is guessed.
Mar 16, 2011
Mar 16, 2031
Oct 30, 2018
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is on file with no resolved reference, so no cap is applied and none is guessed. 2 of 3 maintenance fees are paid so far. Confidence: Medium. from the record
How we calculated this date
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Mar 16, 2011, when application PCT/US2011/028727, the earliest non-provisional in its chain, was filed (this one was filed Mar 1, 2013) | Mar 16, 2031 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer on file (approved), reference document not resolved | no cap applied, and none guessed | Medium confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 2 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | no later than Mar 16, 2031 | Medium confidence |
This family
| Application PCT/US2011/028727 | PCT application no patent term | no patent term |
| US 10,111,830 | this patent no later than Mar 2031 | no later than Mar 2031 |
| Application 13/802,539 | Abandoned not computed | not computed |
| US 10,123,971 | In force no later than Mar 2031 | no later than Mar 2031 |
| Application 13/802,526 | Abandoned not computed | not computed |
Assignments
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Mar 1, 2013 Reel 29909, frame 839 | Patel, Rajesh A.; Bhonsle, Sunil R. | Titan Pharmaceuticals, Inc. | Assignment of Assignor's Interest |
| Feb 2, 2018 Reel 44819, frame 835 | Titan Pharmaceuticals, Inc. | Horizon Credit II LLC, as Assignee of Horizon Technology Finance Corporation | Security Interest |
| Mar 22, 2018 Reel 45669, frame 939 | Horizon Credit II LLC, as Assignee of Horizon Technology Finance Corporation | L. Molteni & C. Dei F.Lli Alitti Società Di Esercizio S.P.A. | Security Interest Assignment and Assumption |
| Oct 5, 2023 Reel 65213, frame 564 | Titan Pharmaceuticals, Inc. | Fedson, Inc. | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
A terminal disclaimer is on file (approved) and its reference document is not resolved. A disclaimer would cap the term earlier than Mar 16, 2031. We will not guess the cap.